Across TCGA pan-cancer cohorts, IL10 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IL10 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher IL10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL10 expression acts as an unfavorable survival marker.
LGG are the cancer types where IL10 Mutation most reproducibly stratifies survival.